The agency issued the alert to the European Center for Disease Prevention and Control (ECDC) after analyzing progress in reducing infections caused by resistant bacteria – often described as “superbugs” – that thrive in healthcare settings.
Instead of meeting the goal of a five percent drop in infections caused by the bacteria common in hospitals Klebsiella pneumoniaethey increased by around 72 percent between 2019 and 2025.
And infections by E.coli The bacteria – which are also resistant to classic antibiotics called cephalosporins – have been set a target of 10 percent reduction. Instead, they increased by more than 16 percent.
System bugs
The WHO said it had found resistance to major antibiotics in at least half of samples from Klebsiella pneumoniae and another common bug, Acinetobacteriain approximately one in two countries in Europe.
Dr Marc-Alain Widdowson, head of health security at WHO/Europe, said that in many countries in the region, “the antibiotics that doctors usually use first are failing to fight serious hospital infections.” When these treatments fail, doctors turn to stronger drugs normally reserved for the most severe cases, called carbapenems.
“When these also stop working, what is essentially left is a small group of last-resort drugs, often expensive and not available in all countries,” he explained. “Each time one of these lines of defense falls, patients move closer to the fact that they no longer have any good options. This is important, because people whose first antibiotic does not work against their infection are more likely to die in hospital.”
WHO noted that of the 51 countries analyzed, 16 still lack a standardized national approach and national coordination, hampering efforts to overcome antimicrobial resistance globally.
In the dark
And in hospitals where few blood samples are taken to identify the bacteria causing an infection, doctors “often have to choose an antibiotic without knowing which one will work,” the agency said.
For patients, this increases the risk of starting treatment with a drug that will not work. And for health systems, “this means planning half-blind,” the WHO stressed, because without reliable data, countries cannot tell where resistance is spreading or whether their efforts to stop it are working. “Better testing would help on both fronts, giving patients the right medicine sooner and countries a clearer view of the threat. »
More positive news, the estimated rate of blood infections caused by resistant bacteria Acinetobacteria has almost halved since the high levels seen in 2021 during the COVID-19 pandemic.
Gn Health
